These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. Sevincok L; Topuz A J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120 [TBL] [Abstract][Full Text] [Related]
4. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647 [TBL] [Abstract][Full Text] [Related]
5. [Validation of a scale for responsibility (Salkovskis Responsibility Scale)]. Bouvard M; Robbe-Grillet P; Milliery M; Pham S; Amireche S; Fanget F; Guerin J; Cottraux J Encephale; 2001; 27(3):229-37. PubMed ID: 11488253 [TBL] [Abstract][Full Text] [Related]
6. Normal and disordered compulsivity: evidence against a continuum. Pitman RK; Jenike MA J Clin Psychiatry; 1989 Dec; 50(12):450-2. PubMed ID: 2600062 [TBL] [Abstract][Full Text] [Related]
7. Lower levels of whole blood serotonin in obsessive-compulsive disorder and in schizophrenia with obsessive-compulsive symptoms. Ma N; Tan LW; Wang Q; Li ZX; Li LJ Psychiatry Res; 2007 Feb; 150(1):61-9. PubMed ID: 17291595 [TBL] [Abstract][Full Text] [Related]
8. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Chouinard G; Goodman W; Greist J; Jenike M; Rasmussen S; White K; Hackett E; Gaffney M; Bick PA Psychopharmacol Bull; 1990; 26(3):279-84. PubMed ID: 2274626 [TBL] [Abstract][Full Text] [Related]
9. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine. Hoehn-Saric R; McLeod DR; Zimmerli WD; Hipsley PA J Clin Psychiatry; 1993 Jul; 54(7):272-6. PubMed ID: 8335655 [TBL] [Abstract][Full Text] [Related]
10. [Self-evaluation of obsessive-compulsive disorder. Adaptation and validation of two psychometric scales to the French version]. Hantouche E; Guelfi JD Encephale; 1993; 19(3):241-8. PubMed ID: 8275910 [TBL] [Abstract][Full Text] [Related]
11. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291 [TBL] [Abstract][Full Text] [Related]
17. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Herrmann N; Rothenburg LS; Black SE; Ryan M; Liu BA; Busto UE; Lanctôt KL J Clin Psychopharmacol; 2008 Jun; 28(3):296-301. PubMed ID: 18480686 [TBL] [Abstract][Full Text] [Related]
18. The presence of magical thinking in obsessive compulsive disorder. Einstein DA; Menzies RG Behav Res Ther; 2004 May; 42(5):539-49. PubMed ID: 15033500 [TBL] [Abstract][Full Text] [Related]
19. Paternal overprotection in obsessive-compulsive disorder and depression with obsessive traits. Yoshida T; Taga C; Matsumoto Y; Fukui K Psychiatry Clin Neurosci; 2005 Oct; 59(5):533-8. PubMed ID: 16194254 [TBL] [Abstract][Full Text] [Related]
20. Perfectionism in depression, obsessive-compulsive disorder and eating disorders. Sassaroli S; Lauro LJ; Ruggiero GM; Mauri MC; Vinai P; Frost R Behav Res Ther; 2008 Jun; 46(6):757-65. PubMed ID: 18394588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]